Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 28:13:857443.
doi: 10.3389/fimmu.2022.857443. eCollection 2022.

Clinical Characteristics of Anti- N-Methyl-d-Aspartate Receptor Encephalitis Overlapping with Demyelinating Diseases: A Review

Affiliations

Clinical Characteristics of Anti- N-Methyl-d-Aspartate Receptor Encephalitis Overlapping with Demyelinating Diseases: A Review

Shujiang Zhang et al. Front Immunol. .

Abstract

Anti-N-methyl-d-aspartate receptor encephalitis (NMDARe), a common autoimmune encephalitis, can be accompanied by demyelinating disorders, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). To compare the clinical characteristics of patients with different overlapping syndromes, we searched the PubMed database and performed a systematic review. Of the 79 patients with overlapping syndromes, 15 had MS, 18 had aquaporin-4-antibody-positive NMOSD (AQP4-Ab-positive NMOSD), and 46 had MOGAD. Compared with classical NMDARe, overlapping syndromes showed atypical symptoms, such as limb weakness, sensory disturbance, and visual impairments in addition to the main symptoms of NMDARe and a lower ratio of ovarian teratoma. Patients with MOGAD overlap were the youngest, while patients with MS and AQP4-Ab-positive NMOSD overlap tended to be older than patients with classical NMDARe. A majority of patients with NMDARe who overlapped with MS or AQP4-Ab-positive NMOSD were female, but this was not the case for patients overlapped with MOGAD. When NMDARe and demyelinating diseases occurred sequentially, the interval was the longest in patients with NMDARe overlapped with MS. A favorable outcome was observed in patients overlapping with MOGAD, but no robust comparison can be drawn with the patients overlapping with AQP4-Ab-positive NMOSD and MS regarding the small number of available data. The long-term prognosis of overlapping syndromes needs further investigation.

Keywords: aquaporin-4-antibody-positive neuromyelitis optica spectrum disorder; demyelinating diseases anti-N-methyl-D-aspartate receptor encephalitis; multiple sclerosis; myelin oligodendrocyte glycoprotein antibody-associated disease; overlapping syndromes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of the study. *Reviews and articles describing patients with a single disease were excluded. **Articles describing patients without key information or aquaporin-4-antibody-negative NMOSD were excluded. There were 15, 18, and 46 NMDARe patients overlapped with MS, AQP4-Ab-positive NMOSD, and MOGAD, respectively.
Figure 2
Figure 2
Details of the sequence of onset in patients with overlapping AQP4-Ab-positive NMOSD or MOGAD. NMDARe, anti-N-methyl-d-aspartate receptor encephalitis; AQP4-Ab-positive NMOSD, aquaporin-4-antibody-positive neuromyelitis optica spectrum disorder; MOGAD, myelin oligodendrocyte glycoprotein antibody-associated disease; NMOSD, neuromyelitis optica spectrum disorder.
Figure 3
Figure 3
Frequencies of atypical symptoms. Sensory disturbance was the most common atypical symptom in patients overlapping with AQP4-Ab-positive NMOSD; limb weakness was the most common atypical symptom in patients overlapping with MOGAD.
Figure 4
Figure 4
Frequencies of MRI lesions in overlapping syndromes. *No basal ganglia involvement in patients overlapped with MS, p = 0.016. Unclassified meant no specific details of MRI abnormalities in original references. White matter refers to all parts of the brain except the paraventricular white matter. Multifocal, infratentorial, and spinal cord involvement all were common in the three overlapping syndromes. Periventricular white matter was the most common lesion site in NMDARe overlapping with MS; periventricular white matter and the temporal lobe were the most common lesion sites in NMDARe overlapping with AQP4-Ab-positive NMOSD; the temporal lobe was the most common lesion site in NMDARe overlapping with MOGAD.

Similar articles

Cited by

References

    1. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical Experience and Laboratory Investigations in Patients With Anti-NMDAR Encephalitis. Lancet Neurol (2011) 10:63–74. doi: 10.1016/S1474-4422(10)70253-2 - DOI - PMC - PubMed
    1. Titulaer MJ, Höftberger R, Iizuka T, Leypoldt F, McCracken L, Cellucci T, et al. . Overlapping Demyelinating Syndromes and Anti–N-Methyl-D-Aspartate Receptor Encephalitis. Ann Neurol (2014) 75:411–28. doi: 10.1002/ana.24117 - DOI - PMC - PubMed
    1. Nan D, Zhang Y, Han J, Jin T. Clinical Features and Management of Coexisting Anti-N-Methyl-D-Aspartate Receptor Encephalitis and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Encephalomyelitis: A Case Report and Review of the Literature. Neurol Sci (2021) 42:847–55. doi: 10.1007/s10072-020-04942-0 - DOI - PubMed
    1. Fan S, Xu Y, Ren H, Guan H, Feng F, Gao X, et al. . Comparison of Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Disease and AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) When They Co-Exist With Anti-NMDA (N-Methyl-D-Aspartate) Receptor Encephalitis. Mult Scler Relat Disord (2018) 20:144–52. doi: 10.1016/j.msard.2018.01.007 - DOI - PubMed
    1. Ding J, Li X, Tian Z. Clinical Features of Coexisting Anti-NMDAR and MOG Antibody-Associated Encephalitis: A Systematic Review and Meta-Analysis. Front Neurol (2021) 12:711376. doi: 10.3389/fneur.2021.711376 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances